Europe Phasing Out of Extraordinary COVID-19 “Regulatory Flexibility”

The European Medicines Agency (EMA), the European Commission (EC) and the Heads of Medicines Agencies (HMA) are phasing out the “extraordinary regulatory flexibilities” that were put in place during the COVID-19 pandemic to ease potential medicine shortages.
Source: Drug Industry Daily